Please login to the form below
Alzheimer's drug
This page shows the latest Alzheimer's drug news and features for those working in and with pharma, biotech and healthcare.
Researchers discover how neurons die in Alzheimer’s disease
They discovered that only human neurons displayed Alzheimer’s features, including tau tangles and neuronal cell loss. ... These findings suggest that humans have specific factors that play in Alzheimer’s that standard mouse models cannot replicate,
Latest news
-
MIT study finds drug candidate reduces inflammation in Alzheimer’s models
s disease (AD) drug, A11, could reduce inflammation and improve memory. ... After comparing the gene expression of immune cells in post-mortem brain samples from AD patients and AD mouse models, researchers found that Alzheimer’s effected major changes
-
Biogen to acquire Reata for approximately $7.3bn
The deal comes just a few weeks after Biogen and Eisai’s jointly developed Alzheimer’s disease drug was granted traditional approval in the US for use in patients with mild ... The FDA’s decision made Leqembi (lecanemab-irmb) the first approved anti
-
Biogen/Eisai’s Alzheimer’s disease drug shows promise as a subcutaneous formulation
Biogen and Eisai’s Alzheimer’s disease drug has shown promise as a subcutaneous (SC) formulation, according to new data presented by Eisai at this year’s Alzheimer’s Association International ... tasks. Eli Lilly also presented results from a late
-
Eli Lilly’s Alzheimer’s drug confirmed to significantly slow disease progression
Eli Lilly’s experimental Alzheimer’s drug has been shown to significantly slow cognitive and functional decline in patients with early symptomatic disease, according to phase 3 results presented at this ... The drug, donanemab, is an intravenous
-
Acumen shares positive results for investigational Alzheimer’s disease therapy at AAIC
The drug, ACU193, works by targeting and binding to amyloid beta oligomers, a toxic and soluble version of the amyloid protein that forms brain plaques associated with Alzheimer’s disease. ... The US Food and Drug Administration has already granted the
More from news
Approximately 7 fully matching, plus 169 partially matching documents found.
Latest Intelligence
-
Alzheimer’s disease: the search for a cure
We are expecting to see the outcomes of an FDA priority review of the potential Alzheimer’s drug, aducanumab, this year. ... Over the past two decades, Alzheimer’s drug discovery has largely focused on targeting the hallmark amyloid protein.
-
Alzheimer’s: the search for a cure
Tau is emerging as a target for drug development in Alzheimer’s, as well as other disorders like frontotemporal dementia. ... Organisations including the Alzheimer’s Drug Discovery Foundation (ADDF) think combinations of molecules with these
-
Detecting Alzheimer’s ahead of a cure
Biogen and Eisai also pulled the plug on their Alzheimer’s drug aducanumab, after advice from an independent data monitoring committee forced them to abandon the phase 3 Abeta-targeting candidate. ... It was just another in a string of late-stage
-
Where next in Alzheimer’s disease R&D?
This evidence has spurred research and led. organisations including the Alzheimer’s Drug Discovery Foundation and AC Immune to conclude that combination therapies may be needed to tackle such a complex ... Read more: Brain power: fresh approaches to
-
Brain power: fresh approaches to Alzheimer’s drug discovery
Two further candidates, AL003 for Alzheimer’s disease and AL004 for multiple degenerative disorders, are also set to enter clinical trials this year. ... Diseases include Alzheimer’s, dementia with Lewy bodies, frontotemporal dementia, as well as
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
Bone Therapeutics looks to Pfizer for clinical head
He has spent a majority of his career at Pfizer, where he held a number of senior roles including medical director for Pfizer Switzerland, European team leader for the Alzheimer's ... disease drug Aricept and medical team leader for its anti-inflammatory
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Top 10 benefits of virtual advisory boards: Save Time and Resources
- NIHR launches new framework to highlight health progress outcomes
- Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases
- UKHSA secures UK-based vaccine deal for future influenza pandemics
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments
- Landscape review reveals £1.1bn of UK funding for rare diseases
No results were found
PMHub
nzyme
The nzyme group focuses on the three fundamentals that enable full patient access - Education, Access & Activation. Our specialist...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
